Current prognostic markers cannot adequately predict the clinical outcome of breast cancer patients. Therefore, additional biomarkers need to be included in routine immune panels. FOXA1 was a significant predictor of favorable outcome in primary breast cancer, while Nestin expression is preferentially found in triple-negative tumors with increased rate of nodal metastases, and reduced survival. | The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases A retrospective study of 164 cases during a 10-year period 2004 2014
